Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TP-0184 |
Synonyms | |
Therapy Description |
TP-0184 inhibits ACVR1 and FLT3 and reduces downstream signaling, potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (PMID: 38007585). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TP-0184 | TP0184|TP 0184|itacnosertib | FLT3 Inhibitor 69 | TP-0184 inhibits ACVR1 and FLT3 and reduces downstream signaling, potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (PMID: 38007585). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | TP-0184 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, TP-0184 inhibited proliferation and growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture, and inhibited tumor growth and improved survival in cell line and patient-derived xenograft models (PMID: 38007585). | 38007585 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04623996 | Phase Ib/II | TP-0184 | A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS | Terminated | USA | 0 |
NCT03429218 | Phase I | TP-0184 | First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors | Completed | USA | 0 |